Clinical Trial Update: 68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial assessing 68Ga-PSMA dual-contrast PET imaging for early detection of hepatocellular carcinoma; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• 68Ga-PSMA-Dual-Contrast PET/MRI

Snippet

Sponsor: Mayo Clinic | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED